Korean J Dermatol.
2008 Apr;46(4):541-543.
Paronychia during Iressa(R) Treatment in a Lung Cancer Patient
- Affiliations
-
- 1Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea. cyb@kuh.ac.kr
- 2Department of Pathology, College of Medicine, Chung Ang University, Seoul, Korea.
Abstract
- Iressa(R) (ZD 1839, gefitinib) is a new anti-cancer agent which selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase in the pathway of the signal transduction. This agent can induce adverse effects in the cutaneous which are related to the interruption of normal epidermal cell kinetics. We report a case of paronychia in a 65-year-old man, developed in both sides of his finger and toe nails during treatment of non-small cell lung cancer (Stage IV) with Iressa(R) for 7 days. The patient came to our clinic with painful periungal inflammation with granulation tissue formation. The lesion was improved after treatment with topical or systemic antibiotics, Burrow's solution (0.3% aluminum acetate) soaking and electrodessication.
Keyword
MeSH Terms
-
Aged
Aluminum
Anti-Bacterial Agents
Carcinoma, Non-Small-Cell Lung
Fingers
Granulation Tissue
Humans
Inflammation
Kinetics
Lung
Lung Neoplasms
Nails
Paronychia
Porphyrins
Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor
Signal Transduction
Toes
Aluminum
Anti-Bacterial Agents
Porphyrins
Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Paronychia, Acneiform Eruption and Dry Skin Induced by Iressa(R)
- Gefitinib-induced Paronychia Teated by Cyosurgery
- Cutaneous Adverse Effects Associated with Iressa(R)(Gefitinib) Medication
- Cutaneous Adverse Reactions Induced by Gefitinib (Iressa) in Lung Cancer Patients
- A Case of Acneiform Eruption and Paronychia Occurring after Use of Erlotinib (Tarceva(R))
